Skip to main content
. Author manuscript; available in PMC: 2019 Apr 23.
Published in final edited form as: Lab Invest. 2018 Oct 23;99(1):85–92. doi: 10.1038/s41374-018-0124-6

Figure 2: (A) Tumors grew in gut of β7−/− B6 mice but not FucTVII−/− B6 mice; (B) tumors grew in skin of FucTVII−/− B6 mice but not β7−/− B6 mice.

Figure 2:

(a) Histology of J558L tumor implantation sites at 9 days after implantation showed large aggregates of CD138/Syndecan+ J558L tumor cells in cecal lamina propria in both BALB/c, and β7−/− B6 recipients, but not in WT B6 or FucTVII−/− B6 mice. Representative histopathology preparations are shown for each (magnifications in parentheses). (b) Tumors grew in skin of FucTVII−/− B6 mice but not β7−/− B6 mice. Histology of J558L tumor implantation sites at 9 days after implantation showed large dermal aggregates of CD138/Syndecan+ J558L tumor cells in both BALB/c and FucTVII−/− B6 recipients, but not in WT B6 or α4β7−/− B6 mice. Representative histopathology preparations are shown for each (magnifications in parentheses).